Emergent BioSolutions, the Baltimore, Maryland-based company manufacturing the Johnson & Johnson coronavirus vaccines, was asked to stop manufacturing COVID-19 related products, while the Food & Drug Administration continues its investigation into quality control issues at the plant that ruined 15 million potential doses of the vaccine. The FDA initiated an inspection of the company’s Bayview facility on April 12. At the request of the FDA, Emergent BioSolutions agreed on April 16 not to make any new COVID-19 materials at this facility and to quarantine existing materials already manufactured there pending results of the inspection.
Johnson & Johnson COVID Vaccine Maker Emergent BioSolutions Asked To Stop Making Doses While FDA Investigation Underway
April 20, 2021